VIP is an abbreviation for vasoactive intestinal peptide, also called vasoactive intestinal polypeptide. Its name reflects the circumstances of discovery, rather than a complete description of every tissue or response in which it is studied. A useful account keeps the ligand, its shared receptors and the particular experimental exposure in view.
Start with the isolated molecule
Said and Mutt’s 1970 report described a 28-residue peptide isolated from porcine small intestine. Chemical and biological comparisons distinguished it from several already known peptides, including secretin and glucagon.Said and Mutt — Isolation of a vasoactive intestinal polypeptide (opens in a new tab)
The discovery establishes a molecular entity and its experimental origin. It does not mean that every later paper using the abbreviation has used the same source material, preparation or measurement.
An article about VIP should therefore identify the ligand explicitly before moving into physiology. A gene-expression result, an immunoreactive signal and an intervention with a defined peptide answer different questions even when all three are described informally as “VIP research”.
| Paper describes | Reader should identify |
|---|---|
| VIP expression | The transcript or protein measurement |
| VIP exposure | The actual experimental ligand and timing |
| VIP receptor activity | The receptor subtype and measured response |
A shared receptor does not merge two ligands
The IUPHAR/BPS VPAC1 receptor record lists VIP alongside PACAP-27 and PACAP-38 as principal endogenous agonists. The human receptor is encoded by VIPR1 and commonly signals through Gs and adenylyl cyclase.IUPHAR/BPS — VPAC1 receptor (opens in a new tab)
VPAC1 is a receptor name; VIP is a ligand name. Keeping those labels in separate columns prevents a response to another agonist at the same receptor from being attributed automatically to VIP.
This distinction becomes especially important when a paper compares VIP with PACAP. Similarity in one receptor system can be the reason for conducting the comparison, while a different response in another system is the result that requires explanation.
A receptor diagram is a starting map. It does not, by itself, predict the duration of a vascular response or the probability of a symptom in a human study.
Why the exposure protocol changes the reading
Amin and colleagues’ 2014 crossover study compared short exposures to PACAP-38 and VIP in women with migraine without aura. Among the 22 participants completing both study days, migraine-like attacks occurred after PACAP-38 in 16 and after VIP in four. This was an active comparison between peptides.Amin and colleagues — PACAP-38 compared with VIP in migraine (opens in a new tab)
A later randomised crossover trial by Pellesi and colleagues used a two-hour VIP exposure and a saline comparator. Migraine attacks were reported in 15 of 21 participants after VIP and one of 21 after placebo during the observation period.Pellesi and colleagues — Prolonged VIP exposure and migraine attacks (opens in a new tab)
These are different protocols and populations, not a single trial randomising participants between short and long VIP exposure. The contrast warns against universalising the earlier finding; it does not isolate duration as the only causal explanation.
Build a claim that retains its boundaries
A precise summary names the peptide, comparator, participant group and outcome. It can then say what happened under that protocol without extending the finding to a different clinical purpose.
For example, evidence that an experimental exposure provokes an outcome is not evidence that administering the peptide treats that condition. A mechanistic challenge study and a therapeutic efficacy trial have different questions.
When two reports appear contradictory, compare their exposure windows and outcome definitions before choosing one as the “correct” story. A difference can be informative even when the studies cannot determine exactly which design feature explains it.
The practical value of this reference is that it keeps VIP identifiable while allowing the research account to change with new evidence. A memorable peptide nickname should never become a substitute for that reading.
Sources and further detail
- Said and Mutt — Isolation of a vasoactive intestinal polypeptide (opens in a new tab)
Original 1970 abstract read for porcine intestinal origin, residue count and chemical distinction.
- IUPHAR/BPS — VPAC1 receptor (opens in a new tab)
Curated ligand, gene and signalling fields read. VPAC1 is kept distinct from PAC1.
- Amin and colleagues — PACAP-38 compared with VIP in migraine (opens in a new tab)
Original 2014 abstract read; active-comparator design and the 22-person completed crossover retained.
- Pellesi and colleagues — Prolonged VIP exposure and migraine attacks (opens in a new tab)
Original 2021 trial abstract, methods and results read. Two-hour exposure, saline comparator and 21-person crossover distinguished from the earlier study.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.